cerrar Actualice su navegador
El navegador que está usando en este momento se encuentra desfasado y no cumple los estándares actuales para páginas web. Si quiere disfrutar una versión actualizada de este y otros sitios web, recomendamos que lo actualice gratuitamente a través de uno de estos enlaces:
Internet Explorer 9 Mozilla Firefox Google Chrome
Health / Salud Volver a "Health / Salud"

The promise and challenge of bespoke cancer treatment

By Elizabeth Allen | 11 de abril de 2012

Our deepening understanding of cancer genetics is allowing us to develop ever-more personalized treatments for individuals. Leading researchers at the Cancer Therapy & Research Center (CTRC) will discuss what they’re learning about how cancer travels through the body and the pros and cons of tailoring specific treatments for each patient at Thursday’s free public lecture at the CTRC at the UT Health Science Center.

La Prensa de San Antonio.- Our deepening understanding of cancer genetics is allowing us to develop ever-more personalized treatments for individuals. Leading researchers at the Cancer Therapy & Research Center (CTRC) will discuss what they’re learning about how cancer travels through the body and the pros and cons of tailoring specific treatments for each patient at Thursday’s free public lecture at the CTRC at the UT Health Science Center.

By Elizabeth A. Allen

Tim Huang, Ph.D., deputy director of the CTRC, will explain the cutting-edge research that is beginning to unlock the puzzle of metastasis at the lecture from 6 p.m. to 7:30 p.m.on the 4th floor of the CTRC’s Grossman Building at 7979 Wurzbach Rd.

“Research shows that some tumor cells break free of the original tumor and circulate in the blood,” Dr. Huang, professor and chair of the department of molecular biology in the School of Medicine at the Health Science Center, said. “These circulating tumor cells, or CTCs, show great promise for being important indicators of how disease progresses, especially for breast, prostate, lung and colon cancers.”

Huang will be joined by Steven Dale Weitman, M.D., Ph.D., director of the Institute for Drug Development at the CTRC. Weitman will discuss developing specific cancer treatments based on the genetic makeup, or signature, of an individual’s cancer.

“With this technology, each patient has the potential to receive a customized therapeutic approach to his or her treatment, with the ultimate goal of enhancing the chance for healing,” Weitman said, “and without exposing patients to therapies that may not work.”

As researchers learn more about this, he added, they are also learning that this strategy has some unexpected hurdles.

“As often happens with cancer, this approach may not be as simple as was originally thought and so the story is still unfolding,” Weitman said.

The goal, with time, will be to design the best and most appropriate therapy for each individual with cancer, he said, eventually leaving behind the “one size fits all” approach to cancer treatment.

This is part of a series of free CTRC monthly public lectures on cancer designed for the general public. The series is sponsored by H-E-B and the Institute for the Integration of Medicine and Science at the UT Health Science Center San Antonio. For more information, call 210-450-1152.

  • Ningún comentario presente
Normas de comentarios

www.laprensasa.com no se hace responsable de las ideas expresadas por los autores de los comentarios y se reserva el derecho a eliminar aquellos contenidos que:
  • resulten ofensivos y/o discriminatorios
  • que tengan como fin promover el boicot contra personas, productos empresas o instituciones
  • que atenten contra el derecho a la intimidad, al honor y/o a la propia imagen o nombre
  • aquellos que busquen fines comerciales y/o publicitarios
500 caracteres disponibles
Para evitar spam, por favor resuelva este simple problema matematico e ingrese el resultado (pinche en la imagen para recargarla).

Health / Salud